Zu Hauptinhalt springen
Startseite UR

PD Dr. Anne Rascle

Rascle Address Institute of Immunology
University Hospital of Regensburg
Franz-Josef-Strauß-Allee 11
93053 Regensburg, Germany
Phone +49 941 944-5467
Homepage E-Mail anne.rascle@klinik.uni-regensburg.de


research

Research Interests

The ‘signal transducer and activator of transcription’ STAT5 is an essential mediator of cytokine signaling. STAT5 deregulation, especially its constitutive activation, directly contributes to tumorigenesis and is associated with a variety of cancers (leukemia, mammary carcinoma, melanoma). Our research focuses on the characterization of the molecular mechanisms of transcriptional regulation by STAT5 in normal and cancer cells.
Our work includes:
- the identification of novel STAT5 target genes encoding proteins or ncRNAs, and the study of their regulation at the chromatin level
- the characterization of epigenetic regulation by STAT5, and its implication in STAT5-mediated cellular transformation

Our ultimate goal is the identification of relevant therapeutic targets for intervention in STAT5-associated cancers.

Methods

- Chromatin and epigenetic studies : Chromatin Immunoprecipitation (ChIP,
   ChIP-on-chip), Chromatin remodeling (CHART-PCR)
- Gene expression studies : Quantitative RT-PCR, microarray-based expression
   profiling, luciferase reporter assays, RNA interference
- Standard molecular and cellular biology methods (DNA, RNA and protein
  manipulation, cell culture)

CV

Curriculum Vitae

Since 09/2010 DFG-funded independent Group Leader at the Institute for Immunology, University of Regensburg, Germany
2009 Habilitation in “Cell Biology”, Faculty of Natural Sciences (NWF III), University of Regensburg, Germany
2004-2010 Project Leader at the Institute for Molecular and Cellular Anatomy, University of Regensburg, Germany
2000-2004 Senior Postdoc/Principal Investigator in the Dpt of Oncology and Discovery Research, DNAX Research Inc. (presently Merck Research Laboratories), Palo Alto, USA
1995-1999 Postdoc in the Dpt of Developmental Biology, Stanford University School of Medicine, USA (Prof. David S. Hogness)
1990-1994 PhD in Molecular and Cellular Biology, Ecole Normale Supérieure de Lyon/University of Lyon, France (Dr. Jacques Samarut)
1985-1990 Graduation in Biology, University of Lyon, France

publications

Recent publications

Rascle, A.*, Neumann, T., Raschta, A-S., Neumann, A., Heining, E., Kastner, J., and Witzgall, R. (2009). The LIM-Homeodomain transcription factor LMX1B regulates expression of NF-kappaB target genes. Exp. Cell Res. 315, 76-96.
Basham, B., Sathe, M., Grein, J., McClanahan, T., d’Andrea, A., Lees, E., and Rascle, A.* (2008). In vivo Identification of Novel STAT5 Target Genes. Nucleic Acids Res. 36, 3802-18.
Suleiman, H., Heudobler, D., Raschta, A-S., Zhao, Y., Zhao, Q., Hertting, I., Vitzthum, H., Moeller, M.J., Holzman, L.B., Rachel, R., Johnson, R., Westphal, H., Rascle, A., and Witzgall, R. (2007). The podocyte-specific inactivation of Lmx1b, Ldb1 and E2a yields new insight into a transcriptional network in podocytes. Dev. Biol. 304, 701-712.
Burrows, J.F., McGrattan, M., Rascle, A., Humbert, M., Baek K-H., and Johnston, J.A. (2004). DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation. J. Biol. Chem. 279, 13993-14000.
Rascle, A.*, Johnston, J.A., and Amati, B. (2003). A deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol. Cell. Biol. 23, 4162-4173.
Rascle, A.*, and Lees, E. (2003). Chromatin acetylation and remodeling at the Cis promoter during STAT5-induced transcription. Nucleic Acids Res. 31, 6882-6890.
Rascle, A.*, Stowers R.S., Garza D., Lepesant J.A., and Hogness D.S. (2003). L63, the Drosophila PFTAIRE, interacts with two novel proteins unrelated to cyclins. Mech. Dev. 120, 617-628.
Migone, T-S.§, Humbert, M.§, Rascle, A.§, Sanden, D., D'Andrea, A., and Johnston, J.A. (2001). The deubiquitinating enzyme Dub-2 prolongs cytokine-induced STAT activation and suppresses apoptosis following cytokine withdrawal. Blood 98, 1935-1941.   § equal contribution
Rascle, A., Ferrand, N., Gandrillon, O., and Samarut, J. (1996). Myb-Ets fusion oncoprotein inhibits T3R/c-ErbA and RAR functions: a novel mechanism of action for leukemogenic transformation by E26 avian retrovirus. Mol. Cell. Biol. 16, 6338-6351.
Rascle, A., Ghysdael, J., and Samarut, J. (1994). c-ErbA, but not v-ErbA, interferes with a putative erythroid repressor for binding to the carbonic anhydrase II promoter. Oncogene 9, 2853-2867.

* corresponding author

  1. UNIVERSITÄT
Rigel-logo3 Homepage Rechte Spalte

RIGeL Flyer (pdf)

RIGeL Handbook (pdf)

'Promotionsordnung' (pdf)